-+ 0.00%
-+ 0.00%
-+ 0.00%

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

Barchart·04/02/2025 06:00:00
Listen to the news

- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - 
- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) -

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.